Literature DB >> 20455057

[Serious course of a miliary tuberculosis in a 34-year-old patient with ulcerative colitis and HIV infection under concomitant therapy with infliximab].

Jonas Zeitz1, Milo Huber, Gerhard Rogler.   

Abstract

A 34-year-old HIV-positive patient with ulcerative colitis was transferred to the authors' hospital because of progressive worsening of his general condition with intermittent fever, increasing lymphopenia, anemia, thrombopenia and neutropenia under anti-tumor necrosis factor-(TNF-)alpha therapy with infliximab. In spite of negative screening tests before initiation of infliximab therapy and intermittent tests during treatment, miliary tuberculosis was finally diagnosed and a tuberculostatic therapy was started. The patient's clinical condition worsened due to the development of a serious exudative necrotizing pancreatitis which was likely to be caused by the tuberculostatic treatment. Due to severe pulmonary infiltrates and pleural effusions with respiratory failure the patient finally passed away.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20455057     DOI: 10.1007/s00063-010-1046-2

Source DB:  PubMed          Journal:  Med Klin (Munich)        ISSN: 0723-5003


  21 in total

1.  A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

Authors:  S R Targan; S B Hanauer; S J van Deventer; L Mayer; D H Present; T Braakman; K L DeWoody; T F Schaible; P J Rutgeerts
Journal:  N Engl J Med       Date:  1997-10-09       Impact factor: 91.245

2.  Disseminated tuberculosis in a Crohn's disease patient on anti-TNF alpha therapy despite chemoprophylaxis.

Authors:  L A Bourikas; I S Kourbeti; A V Koutsopoulos; I E Koutroubakis
Journal:  Gut       Date:  2008-03       Impact factor: 23.059

3.  Performance of two commercial blood IFN-gamma release assays for the detection of Mycobacterium tuberculosis infection in patient candidates for anti-TNF-alpha treatment.

Authors:  M Bocchino; A Matarese; B Bellofiore; P Giacomelli; G Santoro; N Balato; F Castiglione; R Scarpa; F Perna; G Signoriello; D Galati; A Ponticiello; A Sanduzzi
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-05-10       Impact factor: 3.267

4.  Infliximab for induction and maintenance therapy for ulcerative colitis.

Authors:  Paul Rutgeerts; William J Sandborn; Brian G Feagan; Walter Reinisch; Allan Olson; Jewel Johanns; Suzanne Travers; Daniel Rachmilewitz; Stephen B Hanauer; Gary R Lichtenstein; Willem J S de Villiers; Daniel Present; Bruce E Sands; Jean Frédéric Colombel
Journal:  N Engl J Med       Date:  2005-12-08       Impact factor: 91.245

5.  Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial.

Authors:  Stephen B Hanauer; Brian G Feagan; Gary R Lichtenstein; Lloyd F Mayer; S Schreiber; Jean Frederic Colombel; Daniel Rachmilewitz; Douglas C Wolf; Allan Olson; Weihang Bao; Paul Rutgeerts
Journal:  Lancet       Date:  2002-05-04       Impact factor: 79.321

6.  Tumor necrosis factor and its blockade in granulomatous infections: differential modes of action of infliximab and etanercept?

Authors:  Stefan Ehlers
Journal:  Clin Infect Dis       Date:  2005-08-01       Impact factor: 9.079

Review 7.  Treatment of rheumatic diseases in patients with HCV and HIV infection.

Authors:  Mauro Galeazzi; Chiara Giannitti; Stefania Manganelli; Maurizio Benucci; Salvatore Scarpato; Chiara Bazzani; Roberto Caporali; Gian Domenico Sebastiani
Journal:  Autoimmun Rev       Date:  2008-08-09       Impact factor: 9.754

8.  The use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic disease.

Authors:  E J Cepeda; F M Williams; M L Ishimori; M H Weisman; J D Reveille
Journal:  Ann Rheum Dis       Date:  2007-12-13       Impact factor: 19.103

9.  Effective etanercept treatment for psoriatic arthritis complicating concomitant human immunodeficiency virus and hepatitis C virus infection.

Authors:  Garifallia Linardaki; Olga Katsarou; Panagiota Ioannidou; Anastasia Karafoulidou; Kyriaki Boki
Journal:  J Rheumatol       Date:  2007-06       Impact factor: 4.666

10.  Certolizumab pegol for the treatment of Crohn's disease.

Authors:  William J Sandborn; Brian G Feagan; Simeon Stoinov; Pieter J Honiball; Paul Rutgeerts; David Mason; Ralph Bloomfield; Stefan Schreiber
Journal:  N Engl J Med       Date:  2007-07-19       Impact factor: 91.245

View more
  2 in total

Review 1.  Role of pancreatic fat in the outcomes of pancreatitis.

Authors:  Chathur Acharya; Sarah Navina; Vijay P Singh
Journal:  Pancreatology       Date:  2014-07-01       Impact factor: 3.996

2.  Peripancreatic fat necrosis worsens acute pancreatitis independent of pancreatic necrosis via unsaturated fatty acids increased in human pancreatic necrosis collections.

Authors:  Pawan Noel; Krutika Patel; Chandra Durgampudi; Ram N Trivedi; Cristiane de Oliveira; Michael D Crowell; Rahul Pannala; Kenneth Lee; Randall Brand; Jennifer Chennat; Adam Slivka; Georgios I Papachristou; Asif Khalid; David C Whitcomb; James P DeLany; Rachel A Cline; Chathur Acharya; Deepthi Jaligama; Faris M Murad; Dhiraj Yadav; Sarah Navina; Vijay P Singh
Journal:  Gut       Date:  2014-12-10       Impact factor: 23.059

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.